๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanjing
Clinical trial register · China

Clinical Trials in Nanjing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University201 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School89 Nanjing First Hospital, Nanjing Medical University68 The Second Hospital of Nanjing Medical University32 Nanjing Medical University30
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Nanjing

1193 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
NCT07252414Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
180
Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Shanghai, Taiyuan, Hangzhou
2025-12-20
Recruiting
A Multicenter, RAndomlzed, coNtrolled, umBrella Trial fOr Minimally Invasive Neurosurgery With Al-assisted Robotic guidanCe for Hemorrhagic Stroke: Large Basal Ganglia Hemorrhage
NCT06484374Hematoma Brain, Large Basal Ganglia Hemorrhage
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
198
Nanjing
2025-12-20
By invitation
Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy
NCT07371247Esophageal Cancer, MRD, ctDNA
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
65
Nanjing
2025-12-20
Recruiting
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
NCT07225946Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC
Phase 3
800
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanjing, Shanghai, Tianjin
2025-12-19
Recruiting
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
NCT07252739Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 2
140
Nanjing, Nanchang, Shanghai, Chengdu
2025-12-19
Not yet open
Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
NCT07286942NSCLC, NSCLC (Non-small Cell Lung Cancer)
Jiangsu Cancer Institute & Hospital
Phase 2
24
Nanjing
2025-12-18
Recruiting
A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects
NCT07327281Hyperglycemia
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
66
Nanjing
2025-12-18
Recruiting
A Phase II Trial of LM103 in Advanced Melanoma
NCT07310784Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
92
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Changchun
2025-12-16
Recruiting
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
NCT07260708Advanced Cancers
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
42
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Dalian, Jinan
2025-12-16
Recruiting
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
NCT07277439Gastric Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
48
Nanjing
2025-12-16
Recruiting
A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and Patients With Systemic Lupus Erythematosus
NCT07323173Systemic Lupus Erythematosus
Nanjing Leads Biolabs Co.,Ltd
Phase 1
117
Bengbu, Beijing, Guangzhou, Changsha, Nanjing, Pingxiang, Shanghai, Taiyuan
2025-12-16
Not yet open
Multicenter Study on Early Arterial Changes in Prediabetic Patients Evaluated by Ultra-High-Frequency Ultrasound
NCT07271745Prediabetes
Chunyan Ma
Observational
1,740
Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou, Nanjing, Nanchang, Changchun
2025-12-15
Recruiting
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
NCT07127822Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
Peking University
Phase 2
106
Shijiazhuang, Harbin, Zhengzhou, Nanjing, Xi'an, Qingdao, Taiyuan, Chengdu
2025-12-15
Active, closed
Efficacy and Safety of ZT006 in Overweight and Obese Participants
NCT07230132Overweight , Obesity
Beijing QL Biopharmaceutical Co.,Ltd
Phase 2
184
Handan, Langfang, Harbin, Luoyang, Chenzhou, Yueyang, Nanjing, Jinan
2025-12-12
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
NCT07222267Breast Cancer, Advanced Solid Tumor
BeOne Medicines
Phase 1
86
Beijing, Chongqing, Xiamen, Guangzhou, Harbin, Nanjing, Shanghai, Tianjin
2025-12-11
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu
2025-12-11
Recruiting
Effect of Remote Ischemic Preconditioning on Early Neurological Deterioration in Acute Perforating Artery Infarction
NCT07237542Ischemic Stroke, Remote Ischaemic Preconditioning
Jinling Hospital, China
Not applicable
910
Nanjing
2025-12-11
Recruiting
A Real-World Study of Guselkumab in Chinese Participants With Ulcerative Colitis
NCT07302360Colitis, Ulcerative
Xian-Janssen Pharmaceutical Ltd.
Observational
200
Beijing, Changzhou, Guangzhou, Hangzhou, Nanjing, Shijiazhuang, Tianjin
2025-12-11
Recruiting
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
NCT07226349Advanced Solid Tumor
BeOne Medicines
Phase 1
105
Beijing, Guangzhou, Harbin, Wuhan, Nanjing, Jinan, Weifang
2025-12-11
Recruiting
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
NCT07294625Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
36
Zhengzhou, Nanjing, Xuzhou, Shanghai, Xiโ€™an
2025-12-10
Not yet open
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
NCT07277452Pancreatic Cancer, Adult
The First Affiliated Hospital with Nanjing Medical University
Phase 2
156
Nanjing, Beijing
2025-12-10
Recruiting
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
NCT07179679Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
42
Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an
2025-12-09
Active, closed
CMTS0515-auWMT for Radiation Enteritis
NCT07331688Radiation Enteritis
The Second Hospital of Nanjing Medical University
Phase 1/2
60
Nanjing
2025-12-08
Recruiting
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
NCT07340463Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
Nanjing University School of Medicine
Phase 2
50
Nanjing
2025-12-08
Recruiting
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
NCT07230106Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
218
Nanjing, Tianjin
2025-12-08
Not yet open
Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT07266155Paroxysmal Nocturnal Hemoglobinuria
Longbio Pharma
Phase 2
30
Nanjing
2025-12-05
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
NCT07283835Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.
Phase 2
16
Beijing, Chongqing, Fuzhou, Wuhan, Changsha, Nanjing, Shenyang, Jinan
2025-12-04
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229Alzheimer Disease, Agitation
Bristol-Myers Squibb
Phase 3
650
Beijing, Haidian District, Guangzhou, Shenzhen, Changsha, Nanjing, Tianjin, Hangzhou
2025-12-02
Recruiting
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus
AstraZeneca
Phase 1
48
Beijing, Chengdu, Nanjing
2025-12-02
Recruiting
Multicenter Randomized Controlled Trial (RCT) and Efficacy Evaluation System Study on Surgical Innovation Strategies for Neonatal Complex Congenital Heart Disease
NCT07363538Complex Congenital Heart Disease
Central China Fuwai Hospital of Zhengzhou University
Not applicable
738
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Qingdao
2025-12-01
Not yet open
Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer
NCT07261592Bladder Cancer, Histone Deacetylase Inhibitor, Entinostat, Chemotherapy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2
29
Nanjing
2025-12-01
Not yet open
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease
NCT07268807Heart Failure, CKD, Anemia
Zhongda Hospital
Observational
200
Nanjing
2025-12-01
Recruiting
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
NCT06958705Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
The First Affiliated Hospital with Nanjing Medical University
Phase 2
79
Nanjing
2025-12-01
Not yet open
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
NCT07261072Hidradenitis Suppurativa (HS), Hidradenitis Suppurativa (Acne Inversa), Secukinumab
Peking Union Medical College
Phase 4
30
Nanjing
2025-12-01
Recruiting
Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
NCT07530094Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Ning Jiang, M.D./Ph.D.
Phase 2
98
Nanjing
2025-12-01
Recruiting
Exploratory Clinical Trial of Oral Paclitaxel Plus Radiotherapy in Patients With Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
NCT07435454Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
Jiangsu Cancer Institute & Hospital
Phase 2
22
Nanjing
2025-12-01
Not yet open
Application of Quantum Detection-Driven Artificial Intelligence Algorithms for Single-Molecule cfDNA Characterization in the Early Diagnosis of Prostate Cancer
NCT07238959Benign Prostate Hypertrophy(BPH), Prostate Cancer (Diagnosis), Prostate Neoplasm
Shanghai Changzheng Hospital
Observational
1,100
Beijing, Guangzhou, Nanjing, Suzhou, Shanghai, Chengdu, Ningbo
2025-12
Recruiting
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
NCT07246304Small Cell Lung Cancer ( SCLC ), CAR-T Cell Therapy
TCRCure Biopharma Ltd.
Phase EARLY_PHASE1
24
Nanjing
2025-11-30
Recruiting
The Physiological Effect of RCexp on Ventilation/Perfusion Distribution
NCT06919484Acute Respiratory Distress Syndrome, Mechanical Ventilation
Southeast University, China
Observational
60
Nanjing
2025-11-30
Not yet open
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
NCT06177522Pancreatic Cancer, Neoadjuvant Therapy
Jinling Hospital, China
Phase 2
30
Nanjing
2025-11-30
Recruiting
Safety and Efficacy of Anricfen for Postoperative Analgesia and Rehabilitation Promotion After Pancreaticoduodenectomy.Intervention Measures: For Normal Adults, Administer Ariceptin Injection Intravenously Post-operation at a Dose of 1 ฮผg/Kgevery 8 Hours for Three Consecutive Days After Surgery.
NCT07514637Patients Who Undergo Pancreaticoduodenectomy
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
35
Nanjing
2025-11-25
Recruiting
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
NCT07174310Parkinson's Disease
Hoffmann-La Roche
Phase 3
900
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Nanjing
2025-11-24
Not yet open
Subthalamic Nucleus Versus Globus Pallidal Internus Deep Brain Stimulation for Parkinson Disease
NCT07250685PD - Parkinson's Disease
Zhang Jianguo
Not applicable
86
Beijing, Wuhan, Nanjing, Dalian, Jinan, Shanghai, Tianjin, Hangzhou
2025-11-24
Recruiting
A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
NCT07229742Active Lupus Nephritis
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2
51
Nanjing
2025-11-22
Not yet open
Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary Intervention on Acute Myocardial Infarction Patients
NCT06683131Acute Myocardial Infarction (AMI)
The Affiliated Hospital of Xuzhou Medical University
Phase 4
1,160
Fuyang, Huai'an, Lianyungang, Nanjing, Suqian, Xuzhou, Beijing, Shanghai
2025-11-20
Recruiting
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
NCT07343791DC-CIK Treatment, Regorafenib, Colorectal Cancer, Immune Combination Therapy
JIANG LONGWEI
Phase EARLY_PHASE1
14
Nanjing
2025-11-19
Recruiting
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
NCT07363460Lupus Nephritis (LN)
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
105
Nanjing
2025-11-18
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
NCT07161388Limited Stage Small-Cell Lung Cancer
AstraZeneca
Observational
200
Beijing, Cangzhou, Dongguan, Fuzhou, Guangzhou, Huzhou, Jinan, Nanjing
2025-11-17
Recruiting
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
NCT07095868Selected Types of Solid Tumor
Everest Medicines (Beijing) Co., Ltd.
Phase 1/2
94
Changsha, Nanjing, Shanghai
2025-11-17
Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
Beijing Gene Key Life Technology Co., Ltd
Phase 2
48
Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou
2025-11-14
Recruiting
Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
NCT07805967Multiple System Atrophy, Dementia With Lewy Bodies (DLB), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Second Affiliated Hospital of Soochow University
Observational
500
Changshu, Huai'an, Kunshan, Nanjing, Nantong, Suqian, Suzhou, Xuzhou
2025-11-12
Recruiting
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
NCT07361003Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3
464
Fuzhou, Harbin, Nanjing, Jinan, Tianjin, Hangzhou
2025-11-12
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
Eli Lilly and Company
Phase 2
252
Changzhou, Chongqing, Fuzhou, Hangzhou, Kunming, Nanjing, Qingdao, Shenyang
2025-11-10
Active, closed
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
NCT07073820Pulmonary Hypertension
Pfizer
Phase 2
42
Guangzhou, Changsha, Nanjing, Shanghai
2025-11-10
Recruiting
Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease
NCT07228364Autosomal Dominant Polycystic Kidney Disease
AstraZeneca
Phase 1
40
Chengdu, Hangzhou, Nanjing, Shanghai, Wuhan, Xiamen
2025-11-10
Recruiting
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
NCT07265921Advanced Solid Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
232
Beijing, Nanjing, Shanghai, Tianjin, Wuhan
2025-11-07
Active, closed
A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection
NCT07245953Chronic Hepatitis B
Suzhou HepaThera Biotech Co., Ltd.
Phase 2
60
Beijing, Fuzhou, Guangzhou, Qingyuan, Nanning, Zhengzhou, Nanjing, Zhenjiang
2025-11-05
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
NCT07121413Idiopathic Pulmonary Fibrosis(IPF)
Shanghai Synvida Biotechnology Co.,Ltd.
Phase 2
48
Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Neimeng, Shanghai, Tianjin
2025-11-04
By invitation
Consistency of Fluid Tolerance Evaluation Methods and Their Correlation With Clinical Outcomes in Patients With Shock
NCT07373717Shock
Southeast University, China
Observational
45
Nanjing
2025-11-02
Active, closed
Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis
NCT07396467Lung Cancer (Diagnosis), Pulmonary Fibrosis, Interstitial Lung Diseases
The First Affiliated Hospital with Nanjing Medical University
Observational
200
Nanjing
2025-11-01
Not yet open
Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer
NCT07166263Gastric Cancer (GC), Colorectal Cancer
Base Therapeutics (Shanghai) Co., Ltd.
Phase EARLY_PHASE1
15
Nanjing
2025-11
Recruiting
AD-SVF Therapy for Refractory Endometrial Infertility
NCT07230600Endometrium; Atrophy, Intrauterine Synechiae
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1
10
Nanjing
2025-11
Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
NCT07223593Peripheral Arterial Disease
Eli Lilly and Company
Phase 3
1,205
Beijing, Chengdu, Guangzhou, Harbin, Luoyang Shi, Nanjing, Shanghai, Tianjin
2025-10-31
Recruiting
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
NCT07173751Breast Neoplasms
BioNTech SE
Phase 3
558
Changde, Hefei, Jinan, Lanzhou, Linyi, Nanchang, Nanjing, Neijiang
2025-10-30
Active, closed
A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
NCT07220109Respiratory Syncytial Virus Infections
GlaxoSmithKline
Phase 3
750
Beijing, Xiangtan, Nanjing, Chengdu, Chongqing, Guangzhou, Jiujiang, Kunming
2025-10-29
Recruiting
UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
NCT07109986Systemic Lupus Erythematosus, Lupus Nephritis
Nanjing IASO Biotechnology Co., Ltd.
Phase 1
21
Nanjing
2025-10-27
Recruiting
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
NCT07641634Healthy Volunteers, Systemic Sclerosis (SSc), Scleroderma, Systemic, Scleroderma
Prolium Bioscience, Inc
Phase 1/2
44
Beijing, Guangzhou, Nanchang, Nanjing, Pingxiang
2025-10-27
Recruiting
Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis
NCT07263425Leptomeningeal Metastasis of HER2-positive Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
26
Nanjing
2025-10-27
Recruiting
Study on Ketorolac for Improving Outcomes and Prognosis in Patients With Stanford Type A Aortic Dissection
NCT06968806Aortic Dissection, Inflammation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3
1,346
Nanjing
2025-10-27
Recruiting
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
NCT07263386Gastric Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
460
Nanjing
2025-10-23
Recruiting
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
NCT07219173Asthma
Eli Lilly and Company
Phase 2
531
Baotou, Beijing, Chengdu, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai
2025-10-22
Recruiting
An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies
NCT07668453Biliary Tract Neoplasms
The First Affiliated Hospital with Nanjing Medical University
Phase 2
30
Nanjing
2025-10-20
Recruiting
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
NCT07209761Pulmonary Tuberculosis
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
532
Beijing, Fuzhou, Shenzhen, Wuhan, Nanjing, Jinan, Shanghai, Chengdu
2025-10-16
Recruiting
To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.
NCT07303465KRAS G12D Mutations, Pancreatic Ductal Adenocarcinoma (PDAC)
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 2
60
Nanjing, Shanghai
2025-10-14
Recruiting
A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
NCT07095075Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech Co.
Phase EARLY_PHASE1
36
Bengbu, Hefei, Nanjing, Suzhou, Wenzhou
2025-10-14
Recruiting
Sigh Ventilation in Cardiac Surgery
NCT07024420Postoperative Pulmonary Complications (PPCs), Cardiac Surgery in Adult Patient
Zhongda Hospital
Not applicable
686
Nanjing
2025-10-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913Mania, Bipolar Disorder
Bristol-Myers Squibb
Phase 3
424
Beijing, Guangzhou, Baoding, Shijiazhuang, Nanjing, Xi'an, Chengdu, Tianjin
2025-10-08
Not yet open
Anti-IL-5 Therapy With Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP
NCT07200336Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Eye & ENT Hospital of Fudan University
Phase 4
360
Chongqing, Fuzhou, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2025-10-08
Recruiting
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
NCT07185373Primary Central Nervous System Lymphoma
Huashan Hospital
Phase 2/3
215
Beijing, Chengdu, Fuzhou, Guangzhou, Jinan, Nanchang, Nanjing, Shanghai
2025-10-01
Active, closed
Electro-acupuncture for SCD With Depression
NCT07350226Subjective Cognitive Decline (SCD), Depression Disorder
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not applicable
86
Nanjing
2025-10-01
Not yet open
A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.
NCT07156643Locally Advanced Soft Tissue Sarcoma
The First Affiliated Hospital with Nanjing Medical University
Phase 2
46
Nanjing
2025-10-01
Not yet open
Efficacy and Functional Recovery After Switching From Paliperidone Palmitate Injection to Oral Antipsychotics in Schizophrenia
NCT07075237Schizophrenia
Jiangsu Province Nanjing Brain Hospital
Phase 4
120
Nanjing
2025-10
Recruiting
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
NCT07202884Urinary Incontinence,Stress
Eli Lilly and Company
Phase 3
1,000
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Lanzhou, Nanjing
2025-09-30
Recruiting
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
NCT07192614Prostate Cancer
AstraZeneca
Phase 1/2
52
Beijing, Chengdu, Guangzhou, Nanjing
2025-09-30
Not yet open
Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity
NCT07135141Severe Obesity
Beijing Friendship Hospital
Not applicable
256
Beijing, Changsha, Chengdu, Guangzhou, Jinan, Kunming, Nanjing, Shanghai
2025-09-30
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
Bristol-Myers Squibb
Phase 2/3
470
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong
2025-09-30
Not yet open
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
NCT07187284HCC - Hepatocellular Carcinoma
Zhongda Hospital
Phase 1/2
62
Nanjing
2025-09-30
Active, closed
A Phase II Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy
NCT07176702Metastatic PDAC, HER2-positive Status
Shanghai Zhongshan Hospital
Phase 2
45
Nanjing, Shanghai
2025-09-30
Recruiting
Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)
NCT07083154Dementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 3
420
Changsha, Changzhou, Nanjing, Dalian, Shanghai
2025-09-27
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou
2025-09-25
Recruiting
An Exploratory Clinical Study on the Safety and Efficacy of Autologous NK Cells in the Treatment of Pulmonary Nodules
NCT07185035Pulmonary Nodules, Solitary, Pulmonary Nodules, Multiple
The First Affiliated Hospital with Nanjing Medical University
Phase EARLY_PHASE1
24
Nanjing
2025-09-20
Recruiting
A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
NCT07170800Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis
WestVac Biopharma Co., Ltd.
Phase 2
60
Wuhan, Changsha, Nanjing, Jinan, Chengdu, Beijing, Shanghai
2025-09-19
Recruiting
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311Triple-negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Recruiting
HD-tDCS for Adolescent Bipolar Depression Targeting S1
NCT07246044Adolescent, Bipolar Depression, tDCS, Primary Somatosensory Cortex
Jiangsu Province Nanjing Brain Hospital
Not applicable
100
Nanjing
2025-09-16
Recruiting
Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery
NCT07163650Obesity, Weight Loss, Metabolic Surgery
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4
60
Nanjing
2025-09-16
Recruiting
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
NCT07153471Osteoarthritis
Eli Lilly and Company
Phase 3
800
Baotou, Beijing, Chongqing, Harbin, Hefei, Jinan, Luoyang, Nanjing
2025-09-15
Recruiting
Intent of Surgery for IPMN
NCT07216521Intraductal Papillary Mucinous Neoplasm
NYU Langone Health
Observational
2,000
Nanjing
2025-09-15
Recruiting
Local Anaesthetic Spread and Sensory Block Range of the Retro-superior Costotransverse Ligament Space Block
NCT07153263Pulmonary Nodules, Nerve Block
Nanjing First Hospital, Nanjing Medical University
Not applicable
50
Nanjing
2025-09-12
Recruiting
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
NCT07174908Non-Small Cell Lung Cancer
InxMed (Shanghai) Co., Ltd.
Phase 3
400
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang
2025-09-10
Rows per page Showing 301–400 of 1193
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanjing?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,193 of those studies with a site in Nanjing.

How many clinical trials are recruiting in Nanjing?

713 of the 1,193 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 232 have not yet opened recruitment, 216 are active but closed to new participants, and 32 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.